胃泌素释放肽受体、前列腺特异性膜抗原和神经降压素受体1作为前列腺癌精准分层诊断潜在生物标志物的评估
研究在34例前列腺上皮内瘤变、171例前列腺癌和22例淋巴结转移组织中用免疫组化评估GRPR、PSMA和NTR1表达,并分析其与临床病理参数的相关性;16例不同Gleason评分的前列腺癌患者接受68Ga-NOTA-RM26与68Ga-NOTA-PSMA617双示踪剂PET/CT。结果显示PIN阶段GRPR表达显著高于PSMA和NTR1,原发前列腺癌中NTR1表达显著高于PSMA和GRPR;PSMA高表达与更短的无进展生存和总生存相关,高Gleason评分患者68Ga-NOTA-PSMA617肿瘤摄取更高,低Gleason评分患者68Ga-NOTA-RM26肿瘤摄取更高。
要点
- 前列腺上皮内瘤变阶段GRPR表达显著高于PSMA和NTR1(P < 0.001)。
- 原发前列腺癌中NTR1表达显著高于PSMA和GRPR(P = 0.001)。
- 高Gleason评分患者68Ga-NOTA-PSMA617肿瘤摄取更高,低Gleason评分患者68Ga-NOTA-RM26肿瘤摄取更高(均P = 0.001)。
核心结论
- 本研究提出PSMA、GRPR和NTR1三种新型生物标志物作为PET/CT显像剂,可能为前列腺癌的无创精准检测和Gleason分级预测提供有前景的方法。
研究设计与样本
- 免疫组化评估34例前列腺上皮内瘤变、171例前列腺癌和22例淋巴结转移组织中GRPR、PSMA和NTR1的表达,并分析其与前列腺癌患者临床病理参数的相关性。
- 16例不同Gleason评分的前列腺癌患者接受68Ga-NOTA-RM26和68Ga-NOTA-PSMA617双示踪剂PET/CT。
主要发现
- 前列腺上皮内瘤变阶段GRPR表达显著高于PSMA和NTR1(P < 0.001),原发前列腺癌中NTR1表达显著高于PSMA和GRPR(P = 0.001)。
- 前列腺癌患者PSMA高表达与更短的无进展生存(P = 0.037)和总生存(P = 0.035)相关。
- 高Gleason评分前列腺癌患者68Ga-NOTA-PSMA617肿瘤摄取高于低Gleason评分患者(P = 0.001)。
- 低Gleason评分前列腺癌患者68Ga-NOTA-RM26肿瘤摄取高于高Gleason评分患者(P = 0.001)。
临床怎么用
- 原文结论认为这三种生物标志物作为PET/CT显像剂可能为前列腺癌无创精准检测和Gleason分级预测提供有前景的方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Studies on single-target PET imaging of gastrin-releasing peptide receptor (GRPR), prostate-specific membrane antigen (PSMA), or neurotensin receptor 1(NTR1) have been reported. However, the performance of these three targets in the progression of PCa remains unclear. Our study aims to compare the expression of GRPR, PSMA, and NTR1 in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer (PCa), and lymph node metastasis. We synthesized molecular probes targeting the markers to achieve a non-invasive precise detection of PCa patients with PET/CT imaging. METHODS: In this study, the expression of GRPR, PSMA, and NTR1 was evaluated by immunohistochemistry in 34 PIN, 171 PCa, and 22 lymph node metastasis tissues of patients. The correlation between their expression and the clinicopathological parameters of PCa patients was assessed. Sixteen PCa patients with different Gleason scores (GS) underwent dual-tracer (68Ga-NOTA-RM26 and 68Ga-NOTA-PSMA617) PET/CT. RESULTS: In the PIN stage, the expression of GRPR was significantly higher than that of PSMA and NTR1 (P < 0.001), while NTR1 expression was significantly higher than PSMA and GRPR expression in primary PCa (P = 0.001). High PSMA expression in PCa patients was associated with shorter progression-free survival (P = 0.037) and overall survival (P = 0.035). PCa patients with high GS had higher tumor uptake of 68Ga-NOTA-PSMA617 than those with low GS (P = 0.001), while PCa patients with low GS had higher tumor uptake of 68Ga-NOTA-RM26 than those with high GS (P = 0.001). CONCLUSIONS: This study presents three novel biomarkers (PSMA, GRPR, and NTR1) as imaging agents for PET/CT, and may offer a promising approach for non-invasive precise detection and Gleason grade prediction of PCa patients.
引用
- Xiao L, Fang Z, Tang Y, et al. Evaluation of gastrin-releasing peptide receptor, prostate-specific membrane antigen, and neurotensin receptor 1 as potential biomarkers for accurate prostate cancer stratified diagnosis. EJNMMI Res. 2024. PMID: 38880858. doi:10.1186/s13550-024-01116-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。